Skip to main content

Table 1 Demographics of GC patients treated with S-1 adjuvant chemotherapy

From: An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer

Factors

N = 100

Sex (M/F)

73 / 27

Age (< 65/≥65 years)

41 / 59

Tumor size (< 60/≥60 mm)

48 / 52

Histologic type (Diff/Undiff)

35 / 65

pT (1/2/3/4)

5 / 12 / 41 / 42

pN (0/1/2/3)

14 / 25 / 31 / 30

pStage (II/III)

39 / 61

Lymphatic invasion (+/−)

80 / 20

Venous invasion (+/−)

78 / 22

pNLR (+/−)

50 / 50

iNLR (+/−)

26 / 74

fNLR (+/−)

38 / 62

pPLR (+/−)

50 / 50

iPLR (+/−)

50 / 50

fPLR (+/−)

35 / 65

Recurrence (+/−)

35 / 65

Site of relapse (H/P/LYM/Lo)

6 / 12 / 17 / 2

Outcome (D/A)

24 / 76

  1. M, male; F, female; Diff, differentiated type; Undiff, undifferentiated type; pT, pN, pStage = pathological T stage, N stage. Pathological cancer stage according to the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual; pNLR or pPLR, preoperative neutrophil or platelet-to-lymphocyte ratio; iNLR and iPLR, the ratio of the NLR or PLR on the initial day of adjuvant chemotherapy to the pNLR or pPLR; fNLR and fPLR, the ratio of the NLR or PLR on the final day of adjuvant chemotherapy to the iNLR or iPLR; H, hematogenous metastasis; P, peritoneal metastasis; LYM, lymph node metastasis; Lo, local recurrence; D/A, dead or alive